TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT02174549: Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Sponsor: Teclison Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 25 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$9,385,530

Rescue Site Savings

+$6,204,660

Unlock Full NCT02174549 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT02174549 Rescue Dossier →